RxDoctor Payments Data

Elliot Grand, MD

Ophthalmology · Freehold, NJNPI 1184704744

Payments from drug & device makers

$842in general payments, 2019–2025

Across 31 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$350
  • Apellis Pharmaceuticals, Inc.$249
  • AbbVie$137
  • Bausch & Lomb Americas Inc.$33
  • Sun Pharmaceutical Industries Inc.$17
  • Oyster Point Pharma, Inc.$15
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$77091%
  • Education$729%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$842 in reported general payments places this provider in the 35th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$435,350
Medicare patients
1,626
Services billed
5,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost112$57,684
RestasisCyclosporine40$50,490
Alphagan PBrimonidine Tartrate60$35,144
Latanoprost1,758$27,321
SimbrinzaBrinzolamide/Brimonidine Tart69$23,794
XiidraLifitegrast12$22,570
CombiganBrimonidine Tartrate/Timolol27$18,441
Cyclosporine20$17,777
Brinzolamide74$17,122
XalatanLatanoprost16$13,824
Carteolol Hcl485$12,781
RhopressaNetarsudil Mesylate18$12,351
RocklatanNetarsudil Mesylat/Latanoprost19$8,559
Brimonidine Tartrate325$7,965
Travoprost29$7,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$137$161,759239 claims
AlconSimbrinza$350$23,79469 claims
Bausch & Lomb Americas Inc.Xiidra$33$22,57012 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$2,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →